Summit Therapeutics Inc.
SMMT
Kedudukan dalam Saham
#1684
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$15.80
Disegerakkan terakhir: 2026-10-21
Modal Pasaran
$12.61B
Perubahan (1 hari)
-1.78%
Perubahan (1 tahun)
-17.52%
Negara
US
Perdagangan Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Sejarah harga saham bagi Summit Therapeutics Inc. (SMMT)
Harga penutupan tertinggi: $16.40 pada 2026-10-01
Harga penutupan terendah: $11.32 pada 2015-03-01
Harga penutupan terendah: $11.32 pada 2015-03-01
Sejarah harga saham Summit Therapeutics Inc. dari 2015 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | -6.35% |
| 2025 | -2.36% |
| 2024 | 648.94% |
| 2023 | -27.28% |
| 2022 | -16.52% |
| 2021 | -23.50% |
| 2020 | 244.19% |
| 2019 | 23.13% |
| 2018 | -88.74% |
| 2017 | 19.67% |
| 2016 | -15.67% |
| 2015 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $763.55 | 8.53% |
CH
|
